Allogene Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
523
across all filing types
Latest filing
2026-05-28
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-28 | English | |
| 8-K | 2026-05-28 | English | |
| DEFA14A | 2026-05-20 | English | |
| 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47868448 | DEFA14A | 2026-05-28 | English | ||
| 47868481 | 8-K | 2026-05-28 | English | ||
| 46726629 | DEFA14A | 2026-05-20 | English | ||
| 45762022 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | ||
| 34609865 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | ||
| 34439500 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34434910 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34409554 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 32897513 | 4 - ALLOGENE THERAPEUTICS, INC. (0001737287) (Filer) | 2026-03-04 | English | ||
| 31528502 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31528553 | 4 Filing | 2026-02-04 | English | ||
| 31528550 | 4 Filing | 2026-02-04 | English | ||
| 31528532 | 4 Filing | 2026-02-04 | English | ||
| 31528520 | 4 Filing | 2026-02-04 | English | ||
| 31528515 | 4 Filing | 2026-02-04 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orph…
|
ERYP | FR | Manufacturing |
|
Esperion Therapeutics, Inc.
Develops and commercializes oral medicines to reduce cardio…
|
ESPR | US | Manufacturing |
|
ESSA Pharma Inc.
Develops drugs targeting the androgen receptor's N-terminal…
|
EPIX | US | Manufacturing |
|
Essex Bio-Technology Limited
Develops and manufactures biologic drugs using recombinant …
|
1061 | HK | Manufacturing |
|
Estrella Immunopharma, Inc.
Clinical-stage biopharma developing T-cell immunotherapies …
|
ESLA | US | Manufacturing |
|
Eton Pharmaceuticals, Inc.
Pharmaceutical company developing and commercializing treat…
|
ETON | US | Manufacturing |
|
EuBiologics Co., Ltd.
A biopharmaceutical company developing vaccines and offerin…
|
206650 | KR | Manufacturing |
|
Eupraxia Pharmaceuticals Inc.
Clinical-stage biotech developing targeted extended-release…
|
EPRX | CA | Manufacturing |
|
EUPRAXIA PHARMACEUTICALS INC.
Clinical-stage biotech developing locally delivered, extend…
|
EPRX | CA | Manufacturing |
|
Eureka 93 Inc.
Vertically integrated life sciences company focused on CBD …
|
— | CA | Manufacturing |
Allogene Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33378/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33378 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33378 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33378 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33378}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Allogene Therapeutics, Inc. (id: 33378)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.